Kidney Cancer

Patients with advanced renal cell carcinoma who were treated with lenvatinib plus pembrolizumab had health-related quality of life comparable with sunitinib.

In this installment of Clinical Quandaries, Justine Panian, BS, and colleagues present a case of a 60-year-old Mexican woman with fevers, abdominal pain, and hypertension.

At the 15th Annual Interdisciplinary Prostate Cancer Congress® and Other Genitourinary Malignancies, Peter Humphrey, MD, PhD, spoke about the role of pathology in renal cell carcinoma.

Five-year follow-up findings highlighted a durable benefit among patients with advanced renal cell carcinoma following treatment with nivolumab plus ipilimumab compared with sunitinib.

Gennady Bratslavsky, MD, at the 15th Annual Interdisciplinary Prostate Cancer Congress® and Other Genitourinary Malignancies, spoke about which research in renal cell carcinoma has the greatest potential for clinical impact.

Closing out their discussion on renal cell carcinoma management, experts highlight unmet needs and look toward the future treatment landscape.

Following the advent of adjuvant pembrolizumab in high-risk renal cell carcinoma, experts consider treatment strategies for patients who progress on adjuvant pembrolizumab.

Considerations for whether adjuvant pembrolizumab is the new standard of care for patients with renal cell carcinoma at intermediate or high risk of recurrence.

Expert panelists review a clinical scenario of renal cell carcinoma managed with adjuvant pembrolizumab postnephrectomy based on results of the KEYNOTE-564 trial.

At the 15th Annual Interdisciplinary Prostate Cancer Congress® and Other Genitourinary Malignancies, Peter Humphrey, MD, PhD, spoke about how enrollment for specific trials in renal cell carcinoma may incorporate a patient’s tumor histology.

Findings from a preplanned analysis assessing 2 clinical trials of bempegaldesleukin plus nivolumab in renal cell carcinoma and bladder cancer led to a decision to end the combination’s global clinical development program and discontinue all other ongoing clinical trials.

Before closing out their discussion on intermediate-risk RCC, experts review frontline triplet combinations and possible treatment options following relapse after nivolumab-ipilimumab.

Comprehensive discussion on how to best treat patients with renal cell carcinoma and brain or bone metastasis.

Gennady Bratslavsky, MD, spoke about the role of adjuvant therapy in renal cell carcinoma at the 15th Annual Interdisciplinary Prostate Cancer Congress® and Other Genitourinary Malignancies.

In this installement of Clinical Quandaries, Abigail Mateos-Soria, MD, and colleagues present a case of an 38-year-old woman who has a 3-month history of fatigue, dyspnea, significant weight loss, and severe left flank pain.

Shared insight on the adverse event profile of immunotherapy combination regimens in renal cell carcinoma, including advice on when it is appropriate to discontinue therapy.

Expert perspectives on the clinical scenario of a patient with intermediate-risk renal cell carcinoma, who is managed with the immunotherapy combination of ipilimumab and nivolumab.

At the 15th Annual Interdisciplinary Prostate Cancer Congress® and Other Genitourinary Malignancies, Peter Humphrey, MD, PhD, spoke about how the conference catered to the multidisciplinary audience, and what he learned from that.

A look at the factors considered in choosing an appropriate combination treatment for advanced renal cell carcinoma.

Drs Rana McKay and Tom Powles debate the merits of different first-line combination treatment regimens for renal cell carcinoma.

A brief discussion on available treatment options after patients progress following frontline TKI/IO therapy with favorable-risk renal cell carcinoma.

A comprehensive review of the adverse event profiles of TKI/IO regimens used in favorable-risk renal cell carcinoma and how these can be managed with dose adjustment.

Thomas Hutson, DO, PharmD, and Scott Tykodi, MD, PhD, discuss their takeaways from the CLEAR trial and how risk category stratification affected the study.

Brian Shimkus, MD, shares his opinion of data on lenvatinib and pembrolizumab from the CLEAR trial.

Chung-Han Lee, MD, PhD discusses how genetic mutations inform patient prognosis and decision-making for patients with kidney cancer.

Robert Alter, MD opines on the current prognostic value of biomarkers for RCC and the need for additional data in the field.

Mehmet Asim Bilen, MD weighs in on various biomarker testing methodologies, sample considerations, and emerging data on novel biomarkers.

David Aggen, MD, PhD reviews how he currently approaches biomarker testing in patients with RCC.

Mehmet Asim Bilen, MD comments on the prognosis of patients with metastatic RCC and how recent advances have improved outcomes.